ARTICLE | Clinical News

Lixisenatide: Additional Phase III data

October 4, 2010 7:00 AM UTC

Additional data from the double-blind, international Phase III GETGOAL MONO trial in 361 patients showed that a significantly higher proportion of patients receiving 1- and 2-step titrations of once-daily lixisenatide achieved a reduction in HbA1c to <=6.5% vs. placebo at week 12 (25.4% and 31.9%, respectively, p<0.01 for both). The percent values for placebo were not disclosed. Additionally, 1- and 2-step titrations of lixisenatide significantly reduced mean 2-hour postprandial glucose from baseline by 4.51 and 5.47 mmol/L, respectively (p<0.0001 for both). ...